Indian drugmaker Lupin has signed an agreement to acquire US-based Gavis Pharmaceuticals and Novel Laboratories (Gavis) for around $880m.

The acquired business will expand Lupin’s presence in the US generic market, in addition to expanding its portfolio in dermatology, controlled substance products and other niche generics.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Lupin CEO Vinita Gupta said: "Gavis has a strong track record of delivering highly differentiated products in a short time and is poised for continued strong growth as it delivers on its existing pipeline.

"This is a time of globalisation for the specialty pharmaceutical industry and Gavis is well-positioned to capitalise on this exciting opportunity."

Based in New Jersey, Gavis is involved in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products.

Currently, the firm has 66 ANDA filings pending approval with the US FDA, as well as pipeline of around 65 niche dosage forms. The company has also filed 25 Para IVs and eight FTFs products.

According to Lupin, Gavis’ pending filings are expected to have a market value of around $9bn and the combination will include a portfolio of 101 in-market products, 164 cumulative filings pending approval and a pipeline of products under development for the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Lupin will also acquire Gavis manufacturing facility, which will support its inhalation R&D centre in Coral Springs of Florida.

Gavis founder and CEO Dr Veerappan Subramanian said: "This is a time of globalisation for the specialty pharmaceutical industry and Gavis is well-positioned to capitalise on this exciting opportunity."

Lupin develops and markets different branded and generic formulations, as well as biotechnology products and active pharmaceutical ingredients (APIs).

Its products are used in applications, including cardiovascular, diabetology, asthma, paediatric, central nervous system (CNS), and anti-infective.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact